文献速递呼吸道感染

高剂量四价流感疫苗与mRNA-1273加强针在≥65岁成人中同时接种的安全性和免疫原性:一项2期随机开放标签研究

Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
PubMed 文献 · Lancet Respir Med · 2022-02-01

该2期随机开放标签研究在美国6个中心纳入≥65岁、已完成两剂mRNA-1273基础免疫的成人,比较QIV-HD与mRNA-1273加强针同时接种、单独接种QIV-HD或单独接种mRNA-1273的安全性及免疫原性。结果显示同时接种组反应原性与单独mRNA-1273组相似,且对流感株和SARS-CoV-2的抗体反应均与单独接种组相当,未观察到安全性问题或免疫干扰。

要点

  • ≥65岁成人同时接种QIV-HD与mRNA-1273加强针,反应原性与单独接种mRNA-1273相似。
  • 同时接种组流感血凝抑制抗体和SARS-CoV-2结合抗体水平与单独接种组相当。
  • 未报告严重不良事件、特殊关注不良事件或死亡,支持同时接种建议。

核心结论

  • 在≥65岁成人中,QIV-HD与mRNA-1273加强针同时接种未观察到安全性问题或免疫干扰,支持同时接种建议。

研究设计与样本

  • 持续进行的2期、多中心、开放标签、描述性试验,在美国6个临床研究中心开展,报告接种后21天内的中期结果。
  • 社区居住的≥65岁成人,既往已完成两剂mRNA-1273基础免疫且第二剂至少5个月前接种,随机1:1:1分配至同时接种QIV-HD和mRNA-1273、单独接种QIV-HD或单独接种mRNA-1273组。
  • 共306例参与者入组随机,296例至少接种一剂疫苗(同时接种组100例、QIV-HD组92例、mRNA-1273组104例)。

主要发现

  • 7例参与者各报告1例就医不良事件(同时接种组3例、QIV-HD组1例、mRNA-1273组3例),无严重不良事件、特殊关注不良事件或死亡。
  • 第22天流感血凝抑制抗体几何平均滴度在同时接种组与QIV-HD组相似:A/H1N1 363(95%CI 276-476)vs 366(272-491);A/H3N2 286(233-352)vs 315(257-386);B/Yamagata 429(350-525)vs 471(378-588);B/Victoria 377(325-438)vs 390(327-465)。

临床怎么用

  • 对于≥65岁且已完成mRNA-1273基础免疫的成人,可考虑同时接种QIV-HD和mRNA-1273加强针,以减少接种次数并提高接种便利性。
  • 同时接种时需告知患者可能出现的局部和全身反应,其反应原性与单独接种mRNA-1273加强针相似。

局限性

  • 本研究为开放标签设计,未设盲法。
  • 报告的是接种后21天内的中期结果,长期安全性和免疫持久性尚未报告。
  • 研究仅纳入既往接种mRNA-1273基础免疫的社区居住老年人,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Concomitant seasonal influenza vaccination with a COVID-19 vaccine booster could help to minimise potential disruption to the seasonal influenza vaccination campaign and maximise protection against both diseases among individuals at risk of severe disease and hospitalisation. This study aimed to assess the safety and immunogenicity of concomitant administration of high-dose quadrivalent influenza vaccine (QIV-HD) and a mRNA-1273 vaccine booster dose in older adults. METHODS: This study is an ongoing, phase 2, multicentre, open-label, descriptive trial at six clinical research sites in the USA. We describe the interim results up to 21 days after vaccination (July-August, 2021). Community-dwelling adults aged 65 years and older, who were previously vaccinated with a two-dose primary schedule of the mRNA-1273 SARS-CoV-2 vaccine, were eligible for inclusion. The second dose of the primary mRNA-1273 vaccination series was required to have been received at least 5 months before enrolment in the study. Participants were randomly assigned (1:1:1) using a permuted block method stratified by site and by age group (<75 years vs ≥75 years), to receive concomitant administration of QIV-HD and mRNA-1273 vaccine, QIV-HD alone, or mRNA-1273 vaccine alone. Randomisation lists, generated by Sanofi Pasteur biostatistics platform, were provided to study investigators for study group allocation. Unsolicited adverse events occurring immediately, solicited local and systemic reactions up to day 8, and unsolicited adverse events, serious adverse events, adverse events of special interest, and medically attended adverse events up to day 22 were reported. Haemagglutination inhibition antibody responses to influenza A/H1N1, A/H3N2, B/Yamagata, and B/Victoria strains and SARS CoV-2 binding antibody responses (SARS-CoV-2 pre-spike IgG ELISA) were assessed at day 1 and day 22. All analyses were descriptive. The study is registered with ClinicalTrials.gov, NCT04969276. FINDINGS: Between July 16 and Aug 31, 2021, 306 participants were enrolled and randomly assigned, of whom 296 received at least one vaccine dose (100 in the coadministration group, 92 in the QIV-HD, and 104 in the mRNA-1273 group). Reactogenicity profiles were similar between the coadministration and mRNA-1273 groups, with lower reactogenicity rates in the QIV-HD group (frequency of solicited injection site reactions 86·0% [95% CI 77·6-92·1], 91·3% [84·2-96·0], and 61·8% [50·9-71·9]; frequency of solicited systemic reactions 80·0%, [70·8-87·3], 83·7% [75·1-90·2], and 49·4% [38·7-60·2], respectively). Up to day 22, unsolicited adverse events were reported for 17·0% (95% CI 10·2-25·8) of participants in the coadministration group and 14·4% (8·3-22·7) of participants in the mRNA-1273 group, and tended to be reported at a slightly lower rate (10·9% [5·3-19·1]) in participants in the QIV-HD group. Seven participants each reported one medically attended adverse event (three in the coadministration group, one in the QIV-HD group, and three in the mRNA-1273 group). There were no serious adverse events, adverse events of special interest, or deaths. Haemagglutination inhibition antibody geometric mean titres increased from day 1 to day 22 to similar levels in the coadministration and QIV-HD groups, for each influenza strain (A/H1N1: 363 [95% CI 276-476] vs 366 [272-491]; A/H3N2: 286 [233-352] vs 315 [257-386]; B/Yamagata: 429 [350-525] vs 471 [378-588]; B/Victoria: 377 [325-438] vs 390 [327-465] for the coadministration and QIV-HD groups, respectively). SARS-CoV-2 binding antibody geometric mean concentrations also increased to similar levels in the coadministration and mRNA-1273 groups at day 22 (7634 [95% CI 6445-9042] and 7904 [6883-9077], respectively). INTERPRETATION: No safety concerns or immune interference were observed for concomitant administration of QIV-HD with mRNA-1273 booster in adults aged 65 years and older, supporting co-administration recommendations. FUNDING: Sanofi Pasteur.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Izikson R, Brune D, Bolduc JS, et al. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study. Lancet Respir Med. 2022. PMID: 35114141. doi:10.1016/S2213-2600(21)00557-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。